GlassScriptPhysician profile
Clyde L Corey
NPI 1942288394
$5,502.86
in general payments reported to CMS, 2019-2025
34 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $492 · 2021: $371 · 2022: $477 · 2023: $616 · 2024: $1,184 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,115 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.25 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,494.86 | 2019-2025 | Axonics |
| Astellas Pharma US INC | $783.15 | 2019-2025 | Xtandi |
| Endo Pharmaceuticals INC. | $432.05 | 2019-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $305.98 | 2023-2024 | Gemtesa, Myfembree |
| Janssen Biotech, INC. | $303.91 | 2019-2024 | Erleada |
| Abbvie INC. | $213.02 | 2019-2025 | Lupron Depot |
| Urovant Sciences INC | $191.10 | 2022 | |
| Procept Biorobotics Corporation | $184.01 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Endo USA, INC. | $151.34 | 2024-2025 | Xiaflex, Aveed |
| Antares Pharma, INC. | $144.62 | 2019-2025 | Xyosted |
| Urogen Pharma, INC. | $135.49 | 2024 | |
| Coloplast Corp | $116.53 | 2023-2024 | Titan |
| Convatec INC. | $107.02 | 2019-2025 | |
| Pfizer INC. | $105.46 | 2019-2023 | |
| Laborie Medical Technologies Corp. | $99.56 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $97.58 | 2024-2025 | Provenge |
| Allergan, INC. | $58.65 | 2019-2021 | |
| 180 Medical, INC. | $54.24 | 2020-2023 | Cure Catheter |
| Tolmar, INC. | $48.93 | 2024-2025 | Jatenzo, Eligard |
| Edap Technomed INC | $47.61 | 2022-2023 | |
| Axonics, INC. | $45.34 | 2020-2024 | Axonics |
| Bk Medical Holding Company INC. | $43.29 | 2024 | Bk3000, Bk3500 & Bk5000 Ultrasound System |
| Bayer Healthcare Pharmaceuticals INC. | $41.96 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $38.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.63 | 2022-2023 | Seglentis |
| Olympus America INC. | $33.69 | 2024-2025 | Itind System |
| Bluewind Medical | $32.04 | 2025 | Revi |
| Merck Sharp & Dohme LLC | $24.80 | 2024 | Lynparza, Welireg, Keytruda |
| Cook Medical LLC | $23.92 | 2024 | Resonance |
| Tolmar Pharmaceuticals, INC. | $23.28 | 2019 | |
| Halozyme INC | $22.66 | 2023 | |
| Ge Healthcare | $21.81 | 2019 | |
| Metuchen Pharmaceuticals | $21.80 | 2019 | |
| Progenics Pharmaceuticals, INC. | $17.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Corey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.